Batu Biologics Announces FDA Development Plans for ValloVax™

Batu Biologics Announces FDA Development Plans for ValloVax™ Angiogenesis-Targeting Cancer Vaccine
Company Plans to Develop “Next Generation” Govallo Cancer Vaccine, VG-1000, for American Population

Currently the strongest evidence points to Govallo’s Vaccine, termed VG-1000, as working through inhibiting production of new blood vessels in tumors. We are aggressively pursuing this hypothesis as an underlying theme in our developmental experiments.

Read the full article at businesswire.com

Continue →
0

Files Patent Covering its Proprietary Cancer Vaccine

Batu Biologics Files Patent Covering its Proprietary Cancer Vaccine Targeting the Tumor Endothelium: Vallovax
Animal Studies Demonstrate Efficacy in Treatment of Non-Small Cell Lung Cancer

Angiogenesis has proven to be a key factor in the proliferation of tumor cells within the host. Recent studies have revealed that without the formation of new blood vessels, tumors are unable to receive the blood supply they need to grow bigger than 1 to 2 mm in diameter.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Authors Peer-Reviewed Publication

Batu Biologics Authors Peer-Reviewed Publication on Intravenous Vitamin C as Adjuvant to Cancer Immunotherapy
Integration of Holistic Approach to Cancer with Cutting Edge Immunotherapy

Although Batu Biologics is highly focused on the clinical development of ValloVax, a cancer vaccine targeting tumor endothelium, from a corporate perspective we want to ensure that we have the highest possible chance of inducing the most benefit in patients we are treating.

Read the full article at businesswire.com

Continue →
0

Batu Biologics Files Patent

Batu Biologics Files Patent Covering New Use of Approved Drug for Decreasing Cancer Immunotherapy Toxicity
Company Aims to Provide Platform Allowing for Overcoming Rate Limiting Toxicity of Immunotherapy

Several years ago, the promise of immunotherapy was just a dream. Today, with the FDA approval of Provenge, the market entry of immunological checkpoint inhibitors, and the highly encouraging results of the CAR-T cell trials, immunotherapy of cancer is undergoing a renaissance.

Read the full article at businesswire.com

Continue →
0
Page 5 of 5 12345